Complex Regional Pain Syndrome (CRPS) is among the most severe chronic pain conditions known to medicine. Characterized by intense burning pain, swelling, skin changes, and sensitivity to touch, CRPS typically develops after an injury or surgery and involves dysfunction of both the peripheral and central nervous systems. For patients with treatment-resistant CRPS, ketamine tablets have emerged as one potential tool in a multimodal pain management strategy.
Understanding CRPS
CRPS is classified into two types:
- CRPS Type I (formerly reflex sympathetic dystrophy) — develops without confirmed nerve injury, often after fractures, sprains, or surgery
- CRPS Type II (formerly causalgia) — develops after documented nerve damage
Both types share core features:
- Disproportionate pain — far exceeding what would be expected from the original injury
- Sensory changes — allodynia (pain from normally non-painful stimuli like clothing or light touch), hyperalgesia (amplified pain response)
- Vasomotor dysfunction — temperature and color changes in the affected limb
- Sudomotor dysfunction — abnormal sweating patterns
- Motor and trophic changes — weakness, tremor, changes in hair and nail growth
The Budapest Criteria, adopted by the International Association for the Study of Pain (IASP), provide the diagnostic framework. CRPS affects an estimated 26 per 100,000 person-years, with a higher prevalence in women.
Why Ketamine Is Relevant to CRPS
The pathophysiology of CRPS involves several mechanisms where ketamine's pharmacology is directly relevant:
Central Sensitization
CRPS is a prototypical central sensitization disorder. The NMDA receptor plays a critical role in the development and maintenance of central sensitization — the process by which spinal cord and brain neurons become hyperexcitable, amplifying pain signals. Ketamine's primary mechanism as an NMDA receptor antagonist directly targets this process.
Neuroinflammation
CRPS involves significant neuroinflammatory activity, including elevated levels of pro-inflammatory cytokines and glial cell activation. Ketamine has demonstrated anti-inflammatory properties independent of its NMDA receptor effects, including modulation of TNF-alpha, IL-6, and microglial activity.
Wind-Up and Temporal Summation
In CRPS, repeated stimulation of pain pathways leads to progressive amplification — a phenomenon called wind-up. NMDA receptors are essential for wind-up, and ketamine's blockade of these receptors can interrupt this escalating pain cycle.
Sympathetic-Afferent Coupling
Some CRPS presentations involve abnormal coupling between the sympathetic nervous system and sensory nerves. While this mechanism is less directly targeted by ketamine, the reduction in central sensitization may indirectly reduce sympathetically maintained pain.
Evidence for Ketamine in CRPS
IV Ketamine Studies
The strongest evidence base for ketamine in CRPS comes from IV infusion studies:
- A landmark 2009 randomized controlled trial by Sigtermans et al. demonstrated that a 4-day continuous ketamine infusion produced significant pain relief lasting up to 12 weeks in CRPS patients
- Multiple retrospective series have reported response rates of 50–70% for IV ketamine in CRPS, with varying durations of relief
- The Cochrane Database has noted the evidence as "promising but limited by small study sizes"
Oral Ketamine Evidence
Evidence specific to oral ketamine tablets in CRPS is less robust but growing:
Case series and retrospective studies have reported:
- Meaningful pain reduction (30% or greater on visual analog scales) in approximately 40–60% of CRPS patients treated with oral ketamine
- Duration of benefit ranging from weeks to months with continued use
- Some patients able to reduce or eliminate opioid medications after stabilization on oral ketamine
- Improved functional capacity — ability to participate in physical therapy, return to daily activities
Maintenance therapy after IV ketamine is one of the most common use patterns. Patients who respond to an initial IV ketamine infusion series may be transitioned to oral ketamine tablets to maintain the benefits. This approach leverages the potent but temporary effects of IV ketamine while using the more practical oral form for ongoing management.
A 2021 retrospective analysis published in Pain Medicine found that CRPS patients who were transitioned from IV to oral ketamine maintained their pain reduction for significantly longer than those who received IV ketamine alone without oral follow-up.
Dosing Approaches for CRPS
Dosing oral ketamine for CRPS differs from dosing for depression. Pain management typically requires somewhat higher doses, and the dosing schedule is often more frequent.
Typical Starting Protocol
Most pain specialists begin with conservative doses:
- Starting dose: 25–50 mg two to three times daily
- Titration: Increase by 25 mg per dose every 3–7 days as tolerated
- Target range: 100–300 mg total daily dose, divided into 2–4 doses
- Maximum: Generally <400 mg per day, though some specialists use higher doses under close monitoring
Timing Considerations
For CRPS patients, consistent dosing is important because the goal is to maintain steady NMDA receptor blockade. Gaps in coverage can allow central sensitization to re-establish. Many providers prescribe dosing every 6–8 hours to maintain more consistent plasma levels.
For general dosing principles, see our dosing guide and titration protocols.
Combination Therapy
Oral ketamine for CRPS is almost never used as monotherapy. It is typically part of a comprehensive treatment plan that includes:
- Physical and occupational therapy — essential for functional recovery
- Other medications — gabapentinoids, low-dose naltrexone, topical agents, antidepressants
- Interventional procedures — sympathetic nerve blocks, spinal cord stimulation
- Psychological support — pain psychology, cognitive behavioral therapy for chronic pain
What Patients Should Expect
Timeline for Response
Unlike IV ketamine, which can produce rapid pain relief within hours, oral ketamine tablets typically require a longer period to demonstrate benefit in CRPS:
- First 1–2 weeks: Dose titration phase; some patients notice early reduction in pain flares
- Weeks 2–4: Many responders begin to see consistent pain reduction during this period
- Weeks 4–8: Full assessment of response; providers may adjust doses based on pain diaries and functional outcomes
- Beyond 8 weeks: Long-term maintenance if the medication is effective
Measuring Success
In CRPS, "success" with ketamine tablets does not necessarily mean complete pain elimination. Realistic goals include:
- 30% or greater reduction in average daily pain intensity
- Fewer pain flares and reduced severity of breakthrough episodes
- Improved function — ability to participate in rehabilitation, perform daily activities, return to work
- Reduced reliance on opioid or other rescue medications
- Improved sleep — CRPS-related pain frequently disrupts sleep
Side Effects in CRPS Context
Side effects of oral ketamine in CRPS patients are similar to those in other populations:
- Cognitive effects — difficulty concentrating, feeling "foggy." This can be particularly relevant for patients trying to maintain work or academic performance
- Dissociation — mild feelings of detachment at lower doses; dose-limiting at higher doses
- Nausea — manageable with anti-nausea medication and food timing. See our guide on taking tablets on an empty stomach
- Fatigue — often improves as tolerance develops over the first 1–2 weeks
- Urinary symptoms — rare at therapeutic doses but should be monitored, especially with long-term use
The higher doses sometimes needed for CRPS mean side effects may be more prominent than in patients using ketamine for depression. Close communication with your prescriber is essential.
Special Considerations for CRPS Patients
Pediatric CRPS
CRPS is not uncommon in children and adolescents. The use of oral ketamine in pediatric CRPS patients is limited and requires specialized expertise. See our pediatric data article for general information on ketamine in younger patients.
CRPS and Comorbid Depression
CRPS and depression frequently co-occur, with some studies estimating depression prevalence at 50% or higher in CRPS populations. Ketamine's dual action — addressing both pain and mood — makes it particularly relevant for these patients. A single medication targeting both conditions can simplify treatment regimens and reduce the number of concurrent medications.
Opioid Interactions
Many CRPS patients are on opioid therapy when they begin ketamine. Ketamine has been shown to reduce opioid tolerance and may enhance opioid analgesia, potentially allowing for opioid dose reduction over time. This should be managed carefully by the prescribing provider. For more on medication interactions, see our drug interactions guide.
Physical Therapy Timing
Some clinicians recommend timing ketamine tablet doses so that peak effects coincide with physical therapy sessions. The analgesic and potentially anxiolytic effects can improve participation in rehabilitation exercises that would otherwise be too painful.
Finding the Right Provider
Managing CRPS with oral ketamine requires a provider experienced in both chronic pain management and ketamine prescribing. Ideal providers are typically:
- Pain medicine specialists (anesthesiology or physical medicine-trained) with ketamine experience
- Neurologists specializing in complex pain conditions
- Providers at academic medical centers with CRPS programs
See our finding prescribers guide for tips on locating qualified clinicians.
The Bottom Line
Ketamine tablets offer a practical option for CRPS patients who need ongoing NMDA receptor-targeted therapy. While the evidence base is still developing compared to IV ketamine, oral tablets provide a sustainable, home-based approach that fits into the multimodal treatment framework CRPS demands. They are not a standalone solution, but for the right patient — particularly those who have demonstrated a response to IV ketamine — they can be an important component of long-term pain management.
References
- Ketamine for Complex Regional Pain Syndrome: A Systematic Review — Comprehensive review of ketamine evidence in CRPS (Pain Medicine, 2018)
- Sigtermans et al. — Ketamine Infusion for CRPS RCT — Landmark randomized controlled trial of IV ketamine in CRPS (Pain, 2009)
- Central Sensitization in CRPS: Mechanisms and Implications — NIH-indexed review of central sensitization in CRPS pathophysiology
- IASP Budapest Criteria for CRPS Diagnosis — International Association for the Study of Pain diagnostic criteria
- Oral Ketamine as Maintenance Therapy After IV Infusion — Study on transitioning CRPS patients from IV to oral ketamine (Pain Medicine, 2021)
- Neuroinflammation in CRPS — NIH/NINDS resource on CRPS mechanisms and treatments
Share